Thursday, 20 Sep 2018

You are here

The Stress - Autoimmune Disease Connection

"Can stresss be the cause of my autoimmune disease?" is an often launched question met with shrugs of uncertainty or strongly held beliefs rooted in bias moreso than fact.

Swedish investigators have analyzed a large registry cohort and shown that exposure to stress-related disorders yields a significantly increased risk of autoimmune disease. 

They analyzed 106,464 patients with stress-related disorders, with 126,652 full siblings, and over a million non-stressed matched controls to assess a future risk of autoimmune disease. Specifically they looked for 41 autoimmune diseases including rheumatoid arthritis, lupus, ulcerative colitis and Crohn’s disease, celiac disease, multiple sclerosis, and type 1 diabetes.

Overall they found an incidence rate was 9.1 per 1000 person-years in stress exposed patients compared with 6.0 and 6.5 per 1000 person-years in matched (unexposed-control) individuals and siblings, respectively. 

With a mean follow-up of 10 years, the incidence rate of autoimmune diseases  in each group was:

  • Stress disorders: 9.1 per 1000 person-years 
  • Non-Stressed controls: 6.0 per 1000 person-years 
  • Siblings: 6.5 per 1000 person-years

Thus the data suggests a 2.5 to 3 fold increased risk of autoimmune disease in those exposed to stress. For all stress-related disorders the risk of autoimmune disease was increased 36% (HR 1.36 [95% CI, 1.33-1.40]).  For those with posttraumatic stress disorder there was a 46% increased risk (HR 1.46 [95% CI, 1.32-1.61]) for any autoimmune disease  and was also increased for having multiple (≥3) autoimmune diseases (HR 2.29 [95% CI, 1.72-3.04]).

The risks were more pronounced among younger patients (HR, 1.48 for ages ≤33 yrs) and with use of selective serotonin reuptake inhibitors during the first year of PTSD (HR, 3.64 [95% CI, 2.00-6.62]).

These data are surprising as they indirectly show that stress is more important than family genetics (siblings) in influencing the risk of autoimmunity.

The diagnosis of a stress-related disorder and longitudinal follow-up appears to associate with a significantly increased risk of subsequent autoimmune disease. This study does not address the role or contribution of routine daily stressors or situations on subsequent autoimmune risk.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

An Association between GCA and IBD ?

A population based analysis from Israel suggests that giant cell arteritis (GCA) patients may be at increased risk for  inflammatory bowel diseases (IBD) mainly target.

This research was based on sporadic reports in the medical literature (http://bit.ly/2pnIPM0)

Breast Implant Study: More Worries or Not?

The Annals of Surgery reports on an anlaysis of FDA-mandated postmarket studies, including nearly 100,000 breast implant pprocedures, that showed silicone implants to be associated with higher rates of  Sjögren's syndrome, scleroderma, rheumatoid arthritis, stillbirth, and melanoma.

New Classification of Idiopathic Inflammatory Myopathies

Using an observational cohort analysis of patients in the French myositis network, researchers have proposed a new classification of idiopathic inflammatory myopathies (IIM) with four subgroups: dermatomyositis, inclusion body myositis, immune-mediated necrotizing myopathy, and antisynthetase syndrome.

Rsearchers set out to define a classification system for IIM based on phenotypic, biological, and immunologic criteria. 

Depression Increases Risk of Systemic Lupus Erythematosus

Twenty-year data from the Nurses’ Health Study (NHS) suggests that depression is associated with a 2-fold increased frequency of systemic lupus erythematosus (SLE) - the question is why?

Interferon Blocker Disappoints in SLE

Yet another setback has occurred in the efforts to develop new medications for treating systemic lupus erythematosus (SLE), as anifrolumab failed to meet the primary endpoint in a phase III trial, according to AstraZeneca and MedImmune.